Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/1/2017 |
| Start Date: | September 2014 |
| End Date: | September 2025 |
| Contact: | Joanne Weidhaas, MDPhD |
| Email: | joanne@mirakind.org |
| Phone: | 203-671-1308 |
The investigators will recruit and enroll individuals that may have the KRAS-variant or other
microRNA binding site mutations to join registry studies. The investigators will allow
individuals to obtain their results through a physician at the completion of the studies. The
investigators current focus is cancer and autoimmunity.
microRNA binding site mutations to join registry studies. The investigators will allow
individuals to obtain their results through a physician at the completion of the studies. The
investigators current focus is cancer and autoimmunity.
The investigators have identified germ-line microRNA binding site mutations that predict an
increased risk of cancer, endometriosis and associated infertility, and unique tumor biology
and response to treatment. The goal of this protocol is to further determine the mechanisms
of these mutations, such as the KRAS-variant, and their associations with human health, such
as cancer. The investigators will collect saliva samples from individual patients who are
eligible and choose to enroll in these studies, to test for the KRAS-variant and/or other
mutations under study. With specific permission, the investigators will keep excess DNA to
further investigate and discover additional similar mutations. The investigators purpose is
to have participants answer questionnaires about lifestyle factors in an ongoing manner, to
understand the impact of different factors on cancer risk for patients with these mutations.
increased risk of cancer, endometriosis and associated infertility, and unique tumor biology
and response to treatment. The goal of this protocol is to further determine the mechanisms
of these mutations, such as the KRAS-variant, and their associations with human health, such
as cancer. The investigators will collect saliva samples from individual patients who are
eligible and choose to enroll in these studies, to test for the KRAS-variant and/or other
mutations under study. With specific permission, the investigators will keep excess DNA to
further investigate and discover additional similar mutations. The investigators purpose is
to have participants answer questionnaires about lifestyle factors in an ongoing manner, to
understand the impact of different factors on cancer risk for patients with these mutations.
Inclusion Criteria:
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
Exclusion Criteria:
- Younger than 18
- Non-english speaking and unable to understand and sign the consent
We found this trial at
1
site
Click here to add this to my saved trials
